8-K filed January 10, 2025, 6:59 PM ET ticker ERNA CIK 0000748592

other material confidence high sentiment negative materiality 0.75

Eterna receives Nasdaq delisting notice for low MVLS; board changes

Ernexa Therapeutics Inc.

Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.
Company has 180-day cure period (until July 7, 2025) to regain compliance with MVLS standard.
Director Dorothy Clarke resigned Jan 6, 2025; no disagreement with Company; remains general counsel.
Dr. Elena Ratner appointed to Board effective Jan 7, 2025; determined independent director.

item 3.01 item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-001704
form_type: 8-K
ticker: ERNA
cik: 0000748592
company_name: Ernexa Therapeutics Inc.
filed_at: 2025-01-10T23:59:59+00:00
discovered_at: 2026-05-14T18:03:06.260858+00:00
generated_at: 2026-05-28T05:57:05.873599+00:00
sec_items: ["3.01", "5.02"]
event_type: other_material
sentiment: negative
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-001704
json_url: https://secwatch.observer/filing/0001493152-25-001704.json
markdown_url: https://secwatch.observer/filing/0001493152-25-001704.md
text_url: https://secwatch.observer/filing/0001493152-25-001704.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elena Ratner

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2025-01-07
Filed: January 10, 2025, 6:59 PM ET

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Departed

Dorothy Clarke

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2025-01-06
Filed: January 10, 2025, 6:59 PM ET

On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.

Source-grounded claims

437c6abdacadc48b3af075cf859a40b42eba46d5

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

a1168d2254

Elena Ratner was appointed as Director at Ernexa Therapeutics Inc..

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

ed827bf71d

Dorothy Clarke resigned as Director at Ernexa Therapeutics Inc..

On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

Effective May 28, 2026 (the “Effective Date”), the board of directors of Charlotte’s Web Holdings, Inc. (the “Company”), appoint James Jeffery Raborn to the Company’s board of directors

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

John W. Heilshorn, Aaron Spool, Michael Faber, John Ziegelman and Jay Gettenberg (collectively, the “Directors”) were appointed to the board of directors of the Company (the “Board”).

Filing page SEC filing

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Filing page SEC filing

ELOX

Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors

Eloxx Pharmaceuticals, Inc. June 1, 2026, 7:00 AM ET other_material Items 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board

Filing page SEC filing

FDXF

FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed

FedEx Freight Holding Company, Inc. June 1, 2026, 6:46 AM ET other_material Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board

Filing page SEC filing

FXAC

FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross

FortuneX Acquisition Corp May 29, 2026, 5:32 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.

Filing page SEC filing

CRMT

America's Car-Mart forms special committee for strategic alternatives; appoints new independent director

AMERICAS CARMART INC May 29, 2026, 5:30 PM ET other_material Items 1.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: other_material similar materiality

This filing

On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.

Comparable filing

On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.

Filing page SEC filing

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-25-001704

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.